title: Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design.
abstract: The goal of treatment for patients with advanced breast cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction of many cytotoxic agents during the past decade, only modest improvement in survival in metastatic breast cancer has been achieved. In order to improve this situation, new cytotoxic drugs as well as molecule-targeted agents are now under investigation. Bendamustine is a bifunctional alkylating agent with cytotoxic activity against several types of solid tumors. In the search for new anthracycline-free combinations, taxanes and alkylating agents might be worth investigating, in order to reduce cardiac toxicity. In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of bendamustine as a cytotoxic agent in metastatic breast cancer.
authors.affiliation: German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany.
authors.forename: Cristina
authors.initials: C
authors.lastname: Pirvulescu
authors.forename: Gunter
authors.initials: G
authors.lastname: von Minckwitz
authors.forename: Sibylle
authors.initials: S
authors.lastname: Loibl
references.citation: Anticancer Drugs. 2007 Sep;18(8):963-8
references.pmid: 17667603
references.citation: J Cancer Res Clin Oncol. 1998;124(11):627-32
references.pmid: 9860292
references.citation: J Cancer Res Clin Oncol. 2002 Feb;128(2):111-3
references.pmid: 11862482
references.citation: J Clin Oncol. 2006 Dec 1;24(34):5381-7
references.pmid: 17135639
references.citation: Geburtshilfe Frauenheilkd. 1991 May;51(5):383-6
references.pmid: 1869008
references.citation: Cancer. 2004 Jan 1;100(1):44-52
references.pmid: 14692023
references.citation: Anticancer Drugs. 2005 Sep;16(8):871-7
references.pmid: 16096436
references.citation: J Cancer Res Clin Oncol. 2000 Jan;126(1):41-7
references.pmid: 10641748
references.citation: Ann Oncol. 2007 Dec;18(12):1981-4
references.pmid: 17872900
references.citation: Ann Oncol. 2000 Jun;11(6):729-34
references.pmid: 10942063
references.citation: Breast Care (Basel). 2008;3(2):87-92
references.pmid: 21373210
references.citation: Pneumologie. 1998 Oct;52(10):570-3
references.pmid: 9847635
references.citation: J Cancer Res Clin Oncol. 2002 May;128(5):271-8
references.pmid: 12029443
references.citation: Leuk Lymphoma. 2004 Jul;45(7):1429-36
references.pmid: 15359644
references.citation: J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12
references.pmid: 16402269
references.citation: Zentralbl Chir. 1998;123 Suppl 5:156-8
references.pmid: 10063603
references.citation: Clin Cancer Res. 2008 Jan 1;14(1):309-17
references.pmid: 18172283
references.citation: Biochem Pharmacol. 2003 Sep 1;66(5):711-24
references.pmid: 12948851
references.citation: Leukemia. 2002 Oct;16(10):2096-105
references.pmid: 12357363